Anupam Rama
Stock Analyst at JP Morgan
(3.27)
# 854
Out of 4,827 analysts
262
Total ratings
39.62%
Success rate
3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.67 | +499.57% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $35.96 | +225.36% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $117.52 | +56.57% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $34.85 | +43.47% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $11.01 | +272.39% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $29.14 | +75.02% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $2.77 | +297.11% | 7 | Mar 13, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $39 → $34 | $6.76 | +402.96% | 4 | Mar 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $36 → $42 | $19.58 | +114.50% | 11 | Mar 5, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $77 → $71 | $22.02 | +222.43% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $17.81 | +203.20% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $20.44 | +115.26% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $7.77 | +131.66% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $5.32 | +313.53% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $10.02 | +199.40% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $21 | $4.98 | +321.69% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.08 | +179.61% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.80 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $26.72 | +49.70% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $71.60 | +74.58% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.70 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $46.20 | +47.19% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $18.18 | +263.04% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $6.73 | +48.59% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.29 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $36.52 | +379.19% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.09 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $1.70 | +664.71% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.36 | +2,401.39% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.00 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.36 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $7.42 | +3,269.27% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.35 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $32.48 | +78.57% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $9.90 | +21.21% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.41 | +583.92% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $43.92 | +25.23% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.39 | +1,914.39% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $28.04 | +92.58% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.47 | +9,413.74% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $11.30 | +139.04% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $6.70 | +497.01% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $258.35 | -46.97% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.04 | +865.35% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $5.50 | +772.73% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.67 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.85 | +2,019.89% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.58 | +1,798.73% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $42.51 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.70 | - | 2 | Jul 21, 2017 |
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.67
Upside: +499.57%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $35.96
Upside: +225.36%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $117.52
Upside: +56.57%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $34.85
Upside: +43.47%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $11.01
Upside: +272.39%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $29.14
Upside: +75.02%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $2.77
Upside: +297.11%
Day One Biopharmaceuticals
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.76
Upside: +402.96%
AnaptysBio
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $19.58
Upside: +114.50%
Vera Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $22.02
Upside: +222.43%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $17.81
Upside: +203.20%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $20.44
Upside: +115.26%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $7.77
Upside: +131.66%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $5.32
Upside: +313.53%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $10.02
Upside: +199.40%
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $4.98
Upside: +321.69%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.08
Upside: +179.61%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.80
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $26.72
Upside: +49.70%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $71.60
Upside: +74.58%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.70
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $46.20
Upside: +47.19%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $18.18
Upside: +263.04%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $6.73
Upside: +48.59%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $36.52
Upside: +379.19%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $1.70
Upside: +664.71%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.36
Upside: +2,401.39%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.00
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.36
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $7.42
Upside: +3,269.27%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $32.48
Upside: +78.57%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $9.90
Upside: +21.21%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.41
Upside: +583.92%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $43.92
Upside: +25.23%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.39
Upside: +1,914.39%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $28.04
Upside: +92.58%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.47
Upside: +9,413.74%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $11.30
Upside: +139.04%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $6.70
Upside: +497.01%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $258.35
Upside: -46.97%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.04
Upside: +865.35%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $5.50
Upside: +772.73%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $9.67
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.85
Upside: +2,019.89%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.58
Upside: +1,798.73%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $42.51
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.70
Upside: -